Hematogenous dissemination in corpus cancer
- PMID: 11161865
- DOI: 10.1006/gyno.2000.6058
Hematogenous dissemination in corpus cancer
Abstract
Objective: The aim of this study was to assess the predictors of hematogenous dissemination (HD) in corpus cancer.
Methods: In 612 corpus cancer patients managed surgically, we defined HD as tumor spread to the lung, liver, or other sites via hematogenous routes.
Results: We observed 142 instances of tumor spread-71 nonhematogenous and 42 hematogenous to the lung, 9 to the liver, 5 to other sites (adrenals, breast, brain, bone, skin), 3 to both liver and lung, 1 to both lung and bone, and 11 to sites unknown. Stage IV disease, positive adnexae, deep myometrial invasion, primary tumor diameter, tumor involving the whole uterine cavity, positive peritoneal cytology, adjuvant radiotherapy, adjuvant chemotherapy, grade 3 histology, histologic subtype, and lymph-vascular invasion significantly (P < or = 0.01) correlated with HD. However, deep myometrial invasion was the only independent predictor of HD. Only 5% of patients with < or = 50% myometrial invasion had HD compared with 23% with > 50% myometrial invasion. Considering separately recurrence in the lung and in the liver and recurrence in other sites, the only independent predictors of lung recurrence were stage IV disease and myometrial invasion, whereas independent predictors of HD to the liver/other sites were age and histologic grade. Considering only the 60 patients with a known site of HD, 67% with lung recurrence were > 65 years old compared with 17% with HD to the liver/other sites. Furthermore, grade 1-2 disease was observed in 65% of patients with lung recurrence compared with 27% with HD to the liver/other sites.
Conclusions: The presence of deep myometrial invasion was the strongest predictor of HD in corpus cancer, and, together with stage IV disease, it independently predicted lung recurrence. Recurrence in the lung was more frequent in older patients with well or moderately differentiated tumors, whereas HD to the liver/other sites was more frequent in patients < or = 65 years of age harboring grade 3 tumors.
Similar articles
-
High-risk endometrial cancer subgroups: candidates for target-based adjuvant therapy.Gynecol Oncol. 2004 Oct;95(1):120-6. doi: 10.1016/j.ygyno.2004.06.042. Gynecol Oncol. 2004. PMID: 15385120
-
Analysis of FIGO Stage IIIc endometrial cancer patients.Gynecol Oncol. 2001 May;81(2):273-8. doi: 10.1006/gyno.2001.6157. Gynecol Oncol. 2001. PMID: 11330962
-
Patterns of failures in endometrial cancer: clinicopathological variables predictive of the risk of local, distant and retroperitoneal failure.Anticancer Res. 2011 Oct;31(10):3483-8. Anticancer Res. 2011. PMID: 21965765
-
[Multivariate analysis of prognostic factors in endometrial carcinoma].Ai Zheng. 2004 Sep;23(9):1085-8. Ai Zheng. 2004. PMID: 15363208 Chinese.
-
Peritumorous lymph-vascular invasion, grade of histologic differentiation, and myometrial infiltration as prognostic factors of endometrial carcinoma.Rev Paul Med. 1993 May-Jun;111(3):385-90. Rev Paul Med. 1993. PMID: 8108630 Review.
Cited by
-
Circulating Tumor Cell Detection by Liquid Biopsy during Early-Stage Endometrial Cancer Surgery: A Pilot Study.Biomolecules. 2023 Feb 24;13(3):428. doi: 10.3390/biom13030428. Biomolecules. 2023. PMID: 36979364 Free PMC article.
-
Metastatic Endometrioid Carcinoma Mimicking a Subungual Melanoma.Int J Environ Res Public Health. 2022 Nov 4;19(21):14494. doi: 10.3390/ijerph192114494. Int J Environ Res Public Health. 2022. PMID: 36361369 Free PMC article.
-
Therapeutic Benefit of Systematic Lymphadenectomy in Node-Negative Uterine-Confined Endometrioid Endometrial Carcinoma: Omission of Adjuvant Therapy.Cancers (Basel). 2022 Sep 17;14(18):4516. doi: 10.3390/cancers14184516. Cancers (Basel). 2022. PMID: 36139675 Free PMC article. Review.
-
Recurrent Endometrial Cancer: Which Is the Best Treatment? Systematic Review of the Literature.Cancers (Basel). 2022 Aug 29;14(17):4176. doi: 10.3390/cancers14174176. Cancers (Basel). 2022. PMID: 36077713 Free PMC article. Review.
-
Reassessment of intensive surveillance practices adopted for endometrial cancer survivors.BMC Womens Health. 2022 Aug 23;22(1):355. doi: 10.1186/s12905-022-01937-1. BMC Womens Health. 2022. PMID: 35999573 Free PMC article.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical